Translate this page into:
Estimation of effective half life of clearance of radioactive Iodine (131I) in patients treated for hyperthyroidism and carcinoma thyroid
Address for correspondence: Dr. R Ravichandran, Chief Medical Physicist, National Oncology Center, Royal Hospital, PB1331, PC111, Muscat, Sultanate of Oman. E-mail: ravichandranrama@rediffmail.com
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Background:
In medical applications of radioisotopes, for calculations of whole body doses and radiation safety applications, there is a need to estimate radioactive body burden. Local recommendations in Oman stipulate the need for hospitalization of patients treated for radioactive-iodine (131 I) with activities above 400 MBq.
Materials & Methods:
A study of body burden estimation from sequentially measured exposure rates from patients treated for carcinoma thyroid and hyperthyroidism was undertaken. A digital auto-ranging beta gamma survey instrument calibrated for measurement of exposure rates is used in this study.
Results:
The mean measured exposure rates at 1 m in μSv/h immediately after administration and at 24 h intervals are used for estimation of effective half time of clearance of administered activity. For patients with post-operative thyroid carcinoma, the variation of body burden with time post-administration indicated tri-exponential clearance pattern, with T½eff values 14.4 h, 22 h, and 41.3 h. For patients treated for thyrotoxicosis, the body burden showed slow delayed clearance with a T½eff - 111.4 h, and exposure rates did not show appreciable fall off after 48 h.
Keywords
Carcinoma thyroid
body burden
effective half life
iodine-131
INTRODUCTION
Treatments for ablation of functioning thyroid for management of hyperthyroidism and for the elimination of post-surgical residual thyroid tissues in differentiated carcinoma of thyroid by administration of radioactive iodine (RA131 I) are well-established procedures in clinical nuclear medicine. The administered radioactive iodine is absorbed in the functioning thyroid tissue and gets eliminated mainly from the bowel, resulting in whole body dose in addition to being taken up in the glandular tissues of thyroid. The effective half life for clearance of radioactive body burden for normal human subjects is about 5.5 days (about 132 h) which is useful in health physics applications, to calculate the radiation dose received by the thyroid and total body, from the beta and gamma emissions originating from the radioactive iodine. In case of patients treated for carcinoma thyroid, because of surgical removal of thyroid tissues, elimination of administered I-131 radioactivity clears at a faster rate, thereby allowing treatments with large amounts of I-131 as high as 1.85 GBq to 5.5 GBq (50-150 mCi).
The assessment of external radiation exposures from patients at known geometry using radiation monitors is one of the accepted standard methods for estimation of radioactive body burden.[12345] Present regulations in Oman[6] indicates the need for hospitalization of patients above 400 MBq administered activities of RA131 I. We have only two isolation rooms connected with delay tank facility for I-131 treatments. This led to a waiting list for treatments of thyroid cancers in the oncology center. A recent report from Oman[7] has indicated that with good radiation safety instructions to patients and relatives, thyrotoxic patients may be treated as outpatients, provided the patient is physically and mentally fit enough to comply with given instructions. To address the isolation of Omani patients treated with RA131 I in the wards, justifying out-patient treatments for patients with thyrotoxicois and making necessary recommendations regarding their retention period of Ca.thyroid patients, we have analyzed the records of external exposure rates measured from patients who underwent radio-iodine therapy both for differentiated carcinoma thyroid and thyrotoxicosis.
MATERIALS AND METHODS
Patients
The patients who received RA131 I were referred from endocrinology department of the Royal Hospital based on accepted protocols [Table 1]. Patients were accepted for their treatments after obtaining informed consent after these patients were properly explained by the nuclear medicine consultants about the procedure, and possible associated risks. The patients treated during the period 2006 to 2009 were taken up for the study.
Administration of RA 131I
The radioactive iodine is in the form of capsules supplied by GE Healthcare, Amersham, UK. The administrations were carried out on Mondays, and the activities were ordered with reduced activities with reference dates on Thursdays. The radioactive strengths (activity) of the capsules were assayed in Mark V, CalRad Isotope Calibrator (Model 34-164, Nuclear Associates, USA) immediately after arrival of consignment. The containers are labeled with suitable identifications, and activity certificates are prepared in the department. The work flow relating to RA131 I administrations followed in the department is shown in Table 2.
Measurement of exposure rates
Radiation monitoring is carried out using a wide range beta gamma survey meter, auto-ranging with digital reading facility made up of built-in ionization chamber (Inovision, USA). This is hand held type with measuring range 0.1 μSv/h to 100 Sv/h. The exposure rates are measured at 5 cm distance at stomach and neck levels; and at 1 m and 2 m distances with patient sitting on the hospital bed. These measurements are recorded on the first and subsequent days till discharging the patient. Patients are allowed to go home when their exposure rates fall below 10μSv/h (1.0 mR/h) at 1 m distance. This may correspond to retention of residual body burden of about 170 MBq (4.6 mCi).
RESULTS
Table 3 shows the number of patients who received treatments for Ca.thyroid and thyrotoxicosis along with the activities of Ra131 I administered. The mean activities administered were 4.19 GBq and 574.7 MBq for these groups of patients respectively. Table 4 shows the measured mean exposure rates and standard deviation. The number of patients is indicated in brackets. The semi-log plot of these mean exposure rates [Figure 1] gave two distinct patterns of clearance of radioactive body burdens. For patients with post-operative Ca.thyroid, the variation of body burden with time post-administration indicated a tri-exponential pattern. The three slopes of the plots yielded T½eff values 14.4 h, 22.0 h and 41.3 h. For patients treated for thyrotoxicosis, the body burden showed slow rate of clearance with a T½eff =111.4 h, and the exposure rate at 1 m did not show appreciable change after 48 h [Table 4].

DISCUSSION
Our mean exposure rates at 1 m immediately following administration of activity were 88.0 μSv/h (SD 37.6) and 14.9 μSv/h (SD 6), respectively, for the Ca.thyroid and thyrotoxic patients. The results of 1 m exposure rates for thyrotoxic patients 23.4 ± 6.3 μSv/h as reported by Ibtisaam and Bererhi[7] are of the same magnitude. The mean activity of thyrotoxic patients is 574.7 MBq in the present work, to the mean activity of 609.8 MBq reported by these authors. For the patients with thyrotoxicosis, the mean half time of clearance of body burden in our work is T½eff = 111.4 h which is of the order of magnitude quoted by Meredith and Massey,[8] which is 5.5 days (about 136 h).
In our study, the exposure rate at 1 m is averaged over measured values and represented along with the range. This is because of many variables, such as administered activities [Figure 2], various age groups of patients ranging from 18 to 73 years, both sex and different patient weights. For health physics purposes, these values still give an estimate of the risk involved in terms of radiation levels encountered during isolation of these patients.

In the Ca.thyroid patients in the present work, an estimated effective half time of clearance of 14.4 h for body burden is in good agreement with the earlier reported value 11.2-15.4 h[5] in Indian population, and the values reported by Barrington et al,[4] viz. 9.4 h, 13.4 h and 12 h. Thomas et al,[1] compared three methods of body burden estimation viz. 1) urine assay 2) prediction based on a pre-therapy diagnostic work up method using 74 MBq (2 mCi) 3)external exposure rate measurements during actual treatments. They opined that direct external exposure rate surveys showed the potential for being an accurate, reliable and relatively safe method of monitoring patient′s I-131 body burden. From Table 4, it is clearly seen that the exposure rate around the patient treated for thyrotoxicosis remains unchanged after 48 h, seldom reaching the value of 10 μSv/h (1 mR/h) at 1 m because of retention of activity by toxic thyroid.
The Nuclear Regulatory Commission (NRC) specifies patient′s discharge when the body burden falls below about 1100 MBq (30 mCi). However, based on the social and cultural reasons and living conditions in their home, 1100 MBq I-131 appears to be a higher activity limit in Oman. A lower limit of 400 MBq for the patients to be hospitalized (as per prevailing MOH recommendations)[6] will indicate need for hospitalization of all the patients treated for thyrotoxic disorders (above 370MBq). This will make the need for creation of more isolation rooms, which is not practical. Our body burden measurements in thyrotoxic patients treated in the last four years clearly indicate an effective half time of clearance around 114 h (about five days) and no further clearance after 48 h post administration. In this context, it appears that there is no justification in hospitalizing these thyrotoxic patients post administration of I-131 to reduce their body burden to permissible limits, with the presence of healthy thyroid, concentrating bulk of administered activities because of high uptakes. Hospitalization of a few patients for thyrotoxicosis treatments may therefore be selectively restricted to some cases who have infant children around or many inmates living in small homes, justifying reduction of public exposures to permissible levels.
Source of Support
Nil,
Conflicts of interest
None declared.
ACKNOWLEDGEMENTS
Permission from Director General, Royal Hospital, for publication of above work is gratefully acknowledged.
REFERENCES
- A comparison of methods for assessing patient body burden following I-131 therapy for thyroid cancer. Radiology. 1980;137:839-42.
- [Google Scholar]
- Dosimetric considerations while attending hospitalized I-131 therapy patients. J Nucl Med Tech. 1983;10:157-60.
- [Google Scholar]
- Radioiodine therapy for well differentiated thyroid cancer. A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med. 1994;35:1944-50.
- [Google Scholar]
- Radiation doserates from patients receiving Iodine-131 therapy for carcinoma thyroid. Euro J Nucl Med. 1996;23:123-30.
- [Google Scholar]
- Measurement of the radioactive body burden in patients receiving Iodine-131 treatments for carcinoma of the thyroid. Euro J Nucl Med. 1997;24:464.
- [Google Scholar]
- Guidelines on I-131 therapeutic uses. Recommendations from Medical Physics and Radiation Protection Service, DGEA. Sultanate of Oman: Ministry of Health; 2006.
- Radiation exposure levels in family members of Omani patients with thyrotoxicosis treated with radio-iodine (I-131) as outpatients. SQU Med J 2009. ;9:148-52.
- [Google Scholar]
- Fundamental Physics of Radiology (3rd ed). London: John Wright and Sons Ltd; 1977. p. :420-3.
